Treatment-Resistant Depression

🔍 Three Things You Likely Didn’t Know About Treatment-Resistant Depression

1. “Treatment-resistant” frequently means “inadequately treated or mis-diagnosed” While many patients have failed to even get a proper antidepressant trial (Heerlein et al., 2023), others have an unrecognized condition undermining the treatment — unrecognized bipolar disorder, severe unprocessed trauma, or a unique situation where continuing to be depressed has a primary or secondary benefit. The depression may not be resistant — it may simply not have been properly addressed yet.

2. A common anesthetic can lift severe depression in hours. In the early 2000s, NIH researchers gave a subanesthetic dose of a surgical anesthetic to patients who had failed every antidepressant — and their depression lifted within hours (Berman et al., 2000). It was proof that depression could be treated on the timescale of a headache, not a season.

3. About a third of treatment-resistant depression is driven by inflammation — not a neurotransmitter problem. These patients show elevated inflammatory markers in their blood, and their depression doesn’t respond well to standard antidepressants because standard antidepressants aren’t targeting the right mechanism. A recent meta-analysis in the American Journal of Psychiatry confirmed that anti-inflammatory treatment significantly reduces depressive symptoms and anhedonia in patients with elevated inflammation — but only when clinicians actually measure inflammatory markers and select patients accordingly (Mac Giollabhui et al., 2025).

---

📋 Overview

Treatment-resistant depression (TRD) is most commonly defined as major depressive disorder that has not responded adequately to at least two appropriate trials of antidepressant medication, each given at adequate doses for adequate duration. By this definition, TRD affects approximately 30% of all patients treated for depression.

Patients with TRD endure longer depressive episodes, more hospitalizations, higher rates of comorbid anxiety and substance use, greater functional impairment, and significantly elevated suicide risk compared to treatment-responsive depression. Many have been cycling through medications for years, accumulating a history of failed trials that progressively erodes hope — their own and, sometimes, their clinician’s.

At the neurobiological level, TRD appears to involve dysfunction beyond the serotonin and norepinephrine systems targeted by standard antidepressants — including brain inflammation, chronic stress hormone elevation, impaired neuroplasticity, and overactive rumination networks.

The concept of TRD also raises a more fundamental question: is it the depression that is resistant, or is it the treatment that is insufficient? In clinical practice, the answer is often the latter — and the most impactful intervention may not be a new medication but a more thoughtful evaluation.

---

🔀 Why Treatment Fails: A Systematic Framework

Understanding why depression has not responded to treatment is at least as important as knowing what to try next. The major categories include:

• Diagnostic inaccuracy — the most consequential and most correctable factor. Bipolar spectrum illness misdiagnosed as unipolar depression is the classic example: antidepressant monotherapy can actually worsen bipolar depression. ADHD, PTSD, personality disorders, and thyroid disease are important diagnoses that can be missed.
• Inadequate prior trials — doses that were subtherapeutic, durations that were too short (many patients discontinue or switch before reaching the 6–8 weeks needed for full effect), or side effects that led to premature discontinuation without adequate management.
• Unaddressed comorbidities — co-occurring anxiety disorders, substance use, chronic pain, insomnia, and personality pathology.
• Pharmacokinetic factors — genetic variations in drug-metabolizing enzymes, drug-drug interactions, and variable absorption can all produce treatment failure that is pharmacokinetic rather than pharmacodynamic in nature. The medication may simply not be reaching the brain in meaningful doses.
• Psychosocial factors — ongoing exposure to chronic stress, abusive relationships, financial insecurity, social isolation, or unresolved grief can maintain depression in ways that no medication can fully compensate for. Treatment planning must account for the environment and the psychological state, not just the neurotransmitters.
• Neurobiological subtype — the growing recognition that depression is not one disease but many, each with different underlying mechanisms, means that a medication targeting the wrong mechanism may be ineffective regardless of dose or duration. Inflammatory depression, anhedonic depression, anxious depression, and melancholic depression each require different primary treatment strategies.

---

🩺 Diagnosis and Reassessment

The evaluation of treatment-resistant depression is, in many ways, a more demanding clinical task than the initial diagnosis of MDD. It requires:

• Systematic review of prior treatment history — prior medication trials must be reconstructed: agent, dose, duration, reason for discontinuation, degree of response, and side effects. This audit frequently reveals that what appeared to be multiple adequate trials were, in fact, a series of partial, abbreviated, or subtherapeutic exposures.
• Comprehensive diagnostic reassessment — the initial diagnosis must be questioned. Structured screening for bipolar spectrum illness, ADHD, PTSD, personality disorders, and relevant medical conditions should be conducted with fresh eyes.
• Medical workup — thyroid function (including free T3 and T4, not just TSH), inflammatory markers (CRP, ESR), vitamin D, B12, folate, iron studies, metabolic panel, and hormonal assays (testosterone, DHEA, cortisol) may identify modifiable contributors.
• Pharmacogenomic testing — while not universally indicated, pharmacogenomic panels assessing CYP2D6, CYP2C19, and other relevant enzymes can explain prior treatment failures and guide more rational medication selection.
• Sleep assessment — undiagnosed sleep apnea, circadian rhythm disorders, and chronic insomnia are prevalent in treatment-resistant depression and can single-handedly undermine antidepressant efficacy.
• Substance use screening — even moderate alcohol consumption can interfere with antidepressant response, and cannabis, though often used for self-medication, has complex effects on mood circuitry that may perpetuate depression in some individuals.
• Psychosocial assessment — chronic stressors, relational dynamics, occupational factors, primary and secondary gain factors, and unresolved trauma must be formally assessed, not assumed to be “already covered.”

---

💊 Treatment Approach

Psychotherapy

Psychotherapy in treatment-resistant depression is not a consolation prize when medications fail — it is an essential component of a multimodal strategy, and in some cases, the intervention that finally produces a breakthrough.

Acceptance and commitment therapy (ACT) may be particularly valuable in treatment-resistant depression — especially for patients who have developed entrenched hopelessness and treatment fatigue. Rather than making symptom elimination a prerequisite for living, ACT builds the capacity to pursue meaning alongside suffering. Behavioral activation, which directly targets the withdrawal and anhedonia that perpetuate depression, is another evidence-based approach with strong results in TRD.

Medication and Neuromodulation

The pharmacological management of TRD is where clinical expertise, creativity, and deep knowledge of neuropharmacology become most consequential. The standard first-line approach has been exhausted by definition; what follows requires a systematic, evidence-based strategy that draws on the full depth of the pharmacological toolkit.

Neuromodulation offers important additional options. Transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) deliver targeted electromagnetic stimulation to modulate activity in the dorsolateral prefrontal cortex and its connected circuits. TMS is FDA-cleared for treatment-resistant depression and has a growing evidence base. A recently developed high-intensity protocol compresses approximately 90,000 magnetic pulses into five days — the equivalent of six weeks of standard TMS. In a double-blind, sham-controlled trial, 79% of treatment-resistant patients achieved remission (Cole et al., 2022). The durability of this response remains an active area of investigation. Electroconvulsive therapy (ECT), despite its historical stigma, remains the most effective treatment for severe, refractory depression, with response rates of 50–70%. Vagus nerve stimulation (VNS) is FDA-approved for chronic, treatment-resistant depression. Newer neuromodulation approaches continue to emerge, offering additional options for patients who have not responded to other interventions.

The art of treating TRD lies not in knowing the list of available options but in knowing which option to pursue for which patient, in what sequence, at what point.

Integrative and Lifestyle Approaches

Treatment-resistant depression is the population in which attention to neuroinflammation, metabolic health, the gut-brain axis, circadian rhythm optimization, and neuroplasticity-promoting interventions is most critical — because these factors may represent the biological drivers that standard antidepressants were never designed to address.

---

🌱 Outlook

The term “treatment-resistant” is, in many ways, a misnomer — because it implies a static, intractable condition when, in reality, the vast majority of patients with TRD have options that have not yet been explored.

With systematic reassessment, optimized pharmacotherapy, evidence-based augmentation, psychotherapy, and — when appropriate — neuromodulation and integrative approaches, meaningful improvement is achievable for the large majority of patients who carry the TRD label. Even among patients who have failed multiple prior treatments, advanced interventions typically produce response rates of 40–70%.

Recovery from treatment-resistant depression requires more patience, more creativity, and more comprehensive care than standard depression treatment — but the trajectory is far from hopeless. For most patients, it is a matter of finding the right approach for the right biology, guided by a clinician with the experience and persistence to get there.

---

🏥 How to Get Better

At our psychiatry practice, we treat treatment-resistant depression with an evidence-based, multimodal approach — combining precision medication with specialized psychotherapy, and integrating neuromodulation, targeted supplements, stress management, and lifestyle optimization for patients who want every available avenue explored.

Ready to get started? Schedule an intake appointment — a thorough evaluation where we clarify your diagnosis, map out your treatment plan, and get everything moving: medication orders, therapy, supplements, and nutrition. Your care begins the same day, not weeks later.

Schedule Your Intake

We offer statewide telehealth services in California and Florida, with in-person appointments available in Los Angeles and Miami. We also regularly assist international patients due to our fluency in Portuguese, Spanish, and Farsi.

---

📚 References

1. Fava, M. (2003). Diagnosis and definition of treatment-resistant depression. Biological Psychiatry, 53(8), 649–659.
2. Rush, A. J., Trivedi, M. H., Wisniewski, S. R., et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry, 163(11), 1905–1917.
3. Berman, R. M., Cappiello, A., Anand, A., et al. (2000). Antidepressant effects of ketamine in depressed patients. Biological Psychiatry, 47(4), 351–354.
4. Strawbridge, R., Arnone, D., Danese, A., et al. (2015). Inflammation and clinical response to treatment in depression: a meta-analysis. European Neuropsychopharmacology, 25(10), 1532–1543.
5. Heerlein, K., Young, A. H., Otte, C., et al. (2023). Real-world evidence from a European cohort study of patients with treatment-resistant depression. Advances in Therapy, 40, 4825–4846.
6. McIntyre, R. S., Filteau, M. J., Martin, L., et al. (2014). Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. Journal of Affective Disorders, 156, 1–7.
7. Dold, M., & Kasper, S. (2017). Evidence-based pharmacotherapy of treatment-resistant unipolar depression. International Journal of Psychiatry in Clinical Practice, 21(1), 13–23.
8. UK ECT Review Group. (2003). Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. The Lancet, 361(9360), 799–808.
9. Zarate, C. A., Singh, J. B., Carlson, P. J., et al. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry, 63(8), 856–864.
10. Gaynes, B. N., Lloyd, S. W., Lux, L., et al. (2014). Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis. Journal of Clinical Psychiatry, 75(5), 477–489.
11. Nemeroff, C. B. (2007). Prevalence and management of treatment-resistant depression. Journal of Clinical Psychiatry, 68(suppl 8), 17–25.
12. Cole, E. J., Phillips, A. L., Bentzley, B. S., et al. (2022). Stanford Neuromodulation Therapy (SNT): a double-blind randomized controlled trial. American Journal of Psychiatry, 179(2), 132–141.
13. Mac Giollabhui, N., Madison, A. A., Lydston, M., et al. (2025). Effect of anti-inflammatory treatment on depressive symptom severity and anhedonia in depressed individuals with elevated inflammation: systematic review and meta-analysis of randomized controlled trials. American Journal of Psychiatry, 183(1), 70–79.